| Name | Title | Contact Details |
|---|---|---|
Mark Adams |
Chief Information Officer | Profile |
Stellar Biotechnologies is a world leader in the development and manufacture of keyhole limpet hemocyanin (KLH).
Enzyvant is also advancing the development of RVT-802, an investigational tissue-based biologic therapy for the potential treatment of primary immune deficiency associated with complete DiGeorge Syndrome. RVT-802 has been granted orphan drug designation, Breakthrough Therapy designation, Regenerative Medicine Advanced Therapy designation, and pediatric rare disease designation by the U.S. Food and Drug Administration. Enzyvant anticipates a potential BLA filing for RVT-802 in the first half of 2018. Enzyvant plans to develop treatments for additional rare diseases with high unmet need.
Ciitizen is a platform that helps you collect, organize, and share your medical records digitally. Use it to get a second opinion, coordinate with a caregiver, and donate to research.
The Coding Source LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
MultiPlan is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.